


**Intestinal Insulin Signaling Encoded Two Different Molecular Mechanisms for the Shortened Longevity Induced by Graphene Oxide in *Caenorhabditis elegans***

Yunli Zhao,<sup>a, b</sup> Ruilong Yang,<sup>a, c</sup> Qi Rui<sup>c</sup> & Dayong Wang<sup>\*a</sup>


<sup>a</sup>Key Laboratory of Environmental Medicine Engineering in Ministry of Education, Medical School, Southeast University, Nanjing 210009, China

<sup>b</sup>Department of Preventive Medicine, Bengbu Medical College, Bengbu 233020, China


<sup>c</sup>College of Life Sciences, Nanjing Agricultural University, Nanjing 210095, China



**Figure S1 | Physiochemical properties of GO.** (a) TEM of GO in K-medium. (b) AFM analysis of GO. (c) Raman spectrum of GO.



**Figure S2** | Effects of *sod-3* mutation on lifespan in nematodes overexpressing *daf-16* gene in intestine in nematodes. Nematodes were not exposed to GO.



**Figure S3 | Mutation of *sod-3* gene induced the induction of ROS production in GO-exposed nematodes overexpressing *daf-16* gene in intestine.** GO exposure concentration was 100 mg L<sup>-1</sup>. Prolonged exposure was performed from L1-larvae to young adults. Bars represent means ± SEM. \*\**P* < 0.01 vs. wild-type (if not specially indicated).

**Table S1 | Lifespan in *daf-16* or *daf-2* mutants exposed to GO**

Treatment	Mean lifespan (day)	Significance (compared with N2)
Wild-type (control)	15.1 ± 0.6	
Wild-type (100 mg L <sup>-1</sup> GO)	13.2 ± 0.4	
<i>daf-16(mu86)</i> (control)	10.8 ± 0.4	<i>P</i> < 0.01
<i>daf-16(mu86)</i> (100 mg L <sup>-1</sup> GO)	6.5 ± 0.6	<i>P</i> < 0.01
Wild-type (control)	15.2 ± 0.6	
Wild-type (100 mg L <sup>-1</sup> GO)	12.7 ± 0.8	
<i>daf-2(e1370)</i> (control)	23.9 ± 0.7	<i>P</i> < 0.01
<i>daf-2(e1370)</i> (100 mg L <sup>-1</sup> GO)	22.6 ± 0.5	<i>P</i> < 0.01

**Table S2 | Mutations of *age-1*, *akt-1*, *akt-2*, or *daf-18* gene affected the GO toxicity on lifespan in nematodes**

Treatment	Mean lifespan (day)	Significance (compared with control)
Wild-type (control)	15.4 ± 0.6	
Wild-type (100 mg L <sup>-1</sup> GO)	12.5 ± 0.8	
<i>age-1(hx546)</i> (control)	23.4 ± 0.5	<i>P</i> < 0.01
<i>age-1(hx546)</i> (100 mg L <sup>-1</sup> GO)	21.3 ± 0.9	<i>P</i> < 0.01
Wild-type (control)	15.3 ± 0.7	
Wild-type (100 mg L <sup>-1</sup> GO)	12.7 ± 0.3	
<i>akt-1(ok525)</i> (control)	17.1 ± 0.4	<i>P</i> < 0.01
<i>akt-1(ok525)</i> (100 mg L <sup>-1</sup> GO)	16.6 ± 0.3	<i>P</i> < 0.01
Wild-type (control)	15.2 ± 0.5	
Wild-type (100 mg L <sup>-1</sup> GO)	12.4 ± 0.6	
<i>akt-2(ok393)</i> (control)	17.4 ± 0.6	<i>P</i> < 0.01
<i>akt-2(ok393)</i> (100 mg L <sup>-1</sup> GO)	16.9 ± 0.4	<i>P</i> < 0.01
Wild-type (control)	15.1 ± 0.3	
Wild-type (100 mg L <sup>-1</sup> GO)	12.7 ± 0.7	
<i>daf-18(ok480)</i> (control)	11.2 ± 0.6	<i>P</i> < 0.01
<i>daf-18(ok480)</i> (100 mg L <sup>-1</sup> GO)	8.5 ± 0.5	<i>P</i> < 0.01

**Table S3 | Genetic interactions of genes in the insulin signaling pathway in regulating GO toxicity on lifespan in nematode**

Treatment	Mean lifespan (day)	Significance (compared with wild-type)
Wild-type	12.3 ± 0.5	
<i>daf-16(mu86)</i>	8.9 ± 0.7	<i>P</i> < 0.01
<i>daf-2(e1370)</i>	22.4 ± 0.6	<i>P</i> < 0.01
<i>age-1(hx546)</i>	21.7 ± 0.9	<i>P</i> < 0.01
<i>daf-16(mu86);daf-2(e1370)</i>	9.3 ± 0.7	<i>P</i> < 0.01
<i>daf-16(mu86);age-1(hx546)</i>	9.8 ± 0.9	<i>P</i> < 0.01
Wild-type	12.4 ± 0.6	
<i>daf-16(mu86)</i>	8.2 ± 0.8	<i>P</i> < 0.01
<i>akt-1(ok525)</i>	15.9 ± 0.5	<i>P</i> < 0.01
<i>akt-2(ok393)</i>	14.9 ± 0.4	<i>P</i> < 0.01
<i>daf-16(mu86);akt-1(ok525)</i>	8.7 ± 0.6	<i>P</i> < 0.01
<i>daf-16(mu86);akt-2(ok393)</i>	8.3 ± 0.7	<i>P</i> < 0.01
Wild-type	12.5 ± 0.8	
<i>daf-18(ok480)</i>	9.1 ± 0.5	<i>P</i> < 0.01
<i>age-1(hx546)</i>	21.5 ± 0.8	<i>P</i> < 0.01
<i>age-1(hx546);daf-18(ok480)</i>	9.2 ± 0.7	<i>P</i> < 0.01

GO exposure concentration was 100 mg L<sup>-1</sup>.

**Table S4 | Tissue-specific activity of DAF-16 in regulating toxicity of GO on lifespan in nematodes**

Treatment	Mean lifespan (day)	Significance (compared with wild-type)
Wild-type (100 mg L <sup>-1</sup> GO)	11.8 ± 0.7	
<i>daf-16(mu86)</i> (100 mg L <sup>-1</sup> GO)	6.7 ± 0.8	<i>P</i> < 0.01
<i>daf-16(mu86)Ex(Pges-1-daf-16)</i> (100 mg L <sup>-1</sup> GO)	11.1 ± 0.9	NS
<i>daf-16(mu86)Ex(Punc-14-daf-16)</i> (100 mg L <sup>-1</sup> GO)	6.9 ± 1.1	<i>P</i> < 0.01
<i>daf-16(mu86)Ex(Pmyo-3-daf-16)</i> (100 mg L <sup>-1</sup> GO)	6.3 ± 0.5	<i>P</i> < 0.01
<i>daf-16(mu86)Ex(Pmyo-2-daf-16)</i> (100 mg L <sup>-1</sup> GO)	6.2 ± 0.7	<i>P</i> < 0.01

NS, no significance.



**Table S5 | Effects of intestinal RNAi of genes encoding insulin signaling pathway on GO toxicity on lifespan in nematodes**

Treatment	Mean lifespan (day)	Significance (compared with VP303)
VP303 (control)	12.9 ± 0.7	
VP303 (100 mg L <sup>-1</sup> GO)	10.5 ± 0.4	
<i>daf-2</i> intestine RNAi (control)	22.3 ± 0.8	<i>P</i> < 0.01
<i>daf-2</i> intestine RNAi (100 mg L <sup>-1</sup> GO)	20.9 ± 1.2	<i>P</i> < 0.01
<i>daf-16</i> intestine RNAi (control)	10.3 ± 0.5	<i>P</i> < 0.01
<i>daf-16</i> intestine RNAi (100 mg L <sup>-1</sup> GO)	6.7 ± 0.6	<i>P</i> < 0.01
VP303 (control)	13.1 ± 0.4	
VP303 (100 mg L <sup>-1</sup> GO)	10.4 ± 0.5	
<i>age-1</i> intestine RNAi (control)	22.3 ± 0.9	<i>P</i> < 0.01
<i>age-1</i> intestine RNAi (100 mg L <sup>-1</sup> GO)	20.4 ± 0.6	<i>P</i> < 0.01
<i>daf-18</i> intestine RNAi (control)	10.1 ± 0.6	<i>P</i> < 0.01
<i>daf-18</i> intestine RNAi (100 mg L <sup>-1</sup> GO)	7.1 ± 0.6	<i>P</i> < 0.01
VP303 (control)	12.7 ± 0.6	
VP303 (100 mg L <sup>-1</sup> GO)	10.1 ± 0.5	
<i>akt-1</i> intestine RNAi (control)	16.4 ± 1.1	<i>P</i> < 0.01
<i>akt-1</i> intestine RNAi (100 mg L <sup>-1</sup> GO)	15.2 ± 0.9	<i>P</i> < 0.01
<i>akt-2</i> intestine RNAi (control)	16.9 ± 0.8	<i>P</i> < 0.01
<i>akt-2</i> intestine RNAi (100 mg L <sup>-1</sup> GO)	16.1 ± 0.9	<i>P</i> < 0.01

GO)

---

**Table S6 | Effects of intestinal RNAi of *sod-3* gene on GO toxicity on lifespan in nematodes**

Treatment	Mean lifespan (day)	Significance (compared with VP303)
VP303 (control)	13.6 ± 0.8	NS
VP303 (100 mg L <sup>-1</sup> GO)	11.3 ± 0.5	
<i>sod-3</i> intestine RNAi (control)	13.7 ± 0.7	
<i>sod-3</i> intestine RNAi (100 mg L <sup>-1</sup> GO)	8.9 ± 0.7	

NS, no significance.

**Table S7 | Genetic interaction between SOD-3 and DAF-16 in regulating GO toxicity on longevity in nematodes**

Treatment	Mean lifespan (day)	Significance (compared with wild-type)
Wild-type (control)	15.5 ± 0.5	
Wild-type (100 mg L <sup>-1</sup> GO)	12.3 ± 0.4	
<i>Ex(Pges-1-daf-16)</i> (control)	22.7 ± 0.6	<i>P</i> < 0.01
<i>Ex(Pges-1-daf-16)</i> (100 mg L <sup>-1</sup> GO)	21.9 ± 0.8	<i>P</i> < 0.01
Wild-type	14.9 ± 0.8	
<i>Ex(Pges-1-daf-16)</i>	27.6 ± 0.6	<i>P</i> < 0.01
<i>sod-3(gk235)</i>	14.7 ± 0.9	NS
<i>Ex(Pges-1-daf-16);sod-3(gk235)</i>	26.1 ± 0.5	<i>P</i> < 0.01
Wild-type (100 mg L <sup>-1</sup> GO)	12.6 ± 0.5	
<i>Ex(Pges-1-daf-16)</i> (100 mg L <sup>-1</sup> GO)	22.4 ± 0.9	<i>P</i> < 0.01
<i>sod-3(gk235)</i> (100 mg L <sup>-1</sup> GO)	8.6 ± 0.6	<i>P</i> < 0.01
<i>Ex(Pges-1-daf-16);sod-3(gk235)</i> (100 mg L <sup>-1</sup> GO)	9.5 ± 0.8	<i>P</i> < 0.01

NS, no significance.

**Table S8 | Information for RT-PCR primers**

Gene	Forward primer	Reverse primer
<i>tba-1</i>	TCAACACTGCCATCGCCGCC	TCCAAGCGAGACCAGGCTTCAG
<i>daf-2</i>	ATGTGGCGTGAGAATGAA	AGCCGAACACGAACAACA
<i>age-1</i>	ATGGAAACCGCCGAGTGT	ATTGGCAGTCGGTTCAGG
<i>pdk-1</i>	TTCAGAGCCGTCAACCAG	GCTCACTTGCTCGGCTTT
<i>sgk-1</i>	AAGACTGTTGACTGGTGGTG	AGACGAAGTGGCTGGTTG
<i>akt-1</i>	GGACAACCGTTTCCTGAG	GACGAACTTCTGCCGACT
<i>akt-2</i>	ATCAGCCGTTACCAGAGC	AAGGTTTCCTTGACCGAGA
<i>daf-18</i>	ATCATCATCCGCCGAGTC	ACCGTTGAGTCCTCCATC
<i>daf-16</i>	CGTTCCTTCGGATTCA	ATTCCTTCCTGGCTTTGC